Last update: Sept. 2, 2017

Saxagliptin

Low Risk for breastfeeding


Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

It promotes pancreatic insulin secretion by inhibiting the DPP-4 enzyme that degrades the GLP-1 and GIP intestinal hormones involved in the physiological regulation of glucose, which are activated by eating (EMA 2016, Baetta 2011, Scheen 2011). Administered orally, once a day.

Common side effects are upper respiratory tract infections, urinary tract infections, gastrointestinal disorders, and headaches (EMA, 2016).

Very low risk of hypoglycemia in monotherapy. Very low frequency of clinically significant side effects. Doses up to 80 times higher than normal for 2 weeks did not produce side effects (EMA, 2016).

Since the last update we have not found published data on its excretion in breast milk.

Its pharmacokinetic data (EMA 2016, Scheen 2011) and those of its active metabolite (low molecular weight, insignificant protein binding and half-life) make it likely it will pass into breast milk in concentrations that could be significant.

Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.

Diet, exercise, and breastfeeding improve blood sugar levels.


See below the information of these related products:

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Saxagliptin is also known as


Saxagliptin in other languages or writings:

Tradenames

Main tradenames from several countries containing Saxagliptin in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 67 %
Molecular weight 315 daltons
Protein Binding ≈ 0 %
VD 2,2 l/Kg
Tmax 2 - 4 hours
T1/2 2,5 - 3,1 hours

References

  1. EMA. Saxagliptina. Ficha técnica. 2016 Full text (in our servers)
  2. EMA. Saxagliptin. Drug Summary. 2016 Full text (in our servers)
  3. Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother. 2012 Abstract Full text (link to original source)
  4. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs. 2011 Abstract

Total visits

1,124

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by La Liga de la Leche, España from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM